Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

CRN Sports Supplement Guidelines Use “Green Light, Red Light” Model

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Guidelines on the use of sports nutrition supplements by young athletes will be posted on the 1Council for Responsible Nutrition's Web site the week of Oct. 21

You may also be interested in...



GNC ID Policy Aimed At Halting Minors’ Purchases Of Ephedra

GNC will institute a nationwide identification policy in early 2003 for purchasers of products intended for use only by individuals over age 18, the Royal Numico division announced Nov. 6

GNC ID Policy Aimed At Halting Minors’ Purchases Of Ephedra

GNC will institute a nationwide identification policy in early 2003 for purchasers of products intended for use only by individuals over age 18, the Royal Numico division announced Nov. 6

GNC ID Policy Aimed At Halting Minors’ Purchases Of Ephedra

GNC will institute a nationwide identification policy in early 2003 for purchasers of products intended for use only by individuals over age 18, the Royal Numico division announced Nov. 6

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

See All
UsernamePublicRestriction

Register

PS094668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By